Tenax Therapeutics announces the European Patent Office's intention to grant a patent for the use of levosimendan in PH-HFpEF.
The patent will provide protection in Europe through at least December 2040.
It includes protection for TNX-103 (Oral Levosimendan) and other drug formulations, as well as active metabolites, in PH-HFpEF.
Patent Coverage
The patent covers the use of levosimendan, including TNX-103, in treating pulmonary hypertension resulting from heart failure with preserved ejection fraction (PH-HFpEF).
Importance of Patent
This patent protection is crucial for Tenax to seize commercial opportunities in Europe's PH-HFpEF market, mirroring North American patient estimates.
Global IP Portfolio Strength
The new patent complements existing U.S. and Canadian patents, enhancing Tenax's global IP portfolio for their novel cardiopulmonary therapies.
- The patent enhances Tenax's IP protection, particularly in Europe where prevalence of PH-HFpEF is significant.
- It strengthens Tenax's position as they prepare for the Level-2 Phase 3 study, crucial for regulatory approval and international patient inclusion.
The European Patent Office's decision to grant the patent marks a significant milestone for Tenax Therapeutics, reinforcing their position in the PH-HFpEF treatment market.